LIVER DAMAGE IN PATIENTS WITH GASTRIC AND DUODENAL ULCERS IN CHRONIC HELICOBACTER PYLORI INFECTION
DOI:
https://doi.org/10.32782/2226-2008-2026-1-13Keywords:
Gastric ulcer, duodenal ulcer, chronic Helicobacter pylori infection, liver, Helicobacter PyloriAbstract
The purpose. To identify and determine the state of the liver according to the activity of hepatic enzymes and ultrasound diagnostic data in patients with gastric and duodenal ulcers in chronic helicobacteriosis. Materials and methods. 54 gastroenterological patients (21 men and 34 women) with gastric and duodenal ulcer caused by chronic Helicobacter pylori infection and a control group of patients (n = 20) have been examined. Control group patients additionally underwent biochemical blood tests. Results. During a comprehensive examination of the main group patients concomitant pathology was detected: chronic pancreatitis, chronic acalculous cholecystitis, post-cholecystectomy syndrome, arterial hypertension, ischemic heart disease, chronic kidney disease was diagnosed in patients. The average degree of contamination of the gastric mucosa with inactive forms of Helicobacter pylori infection by topographic zones was analyzed. In the majority of gastric and duodenal ulcer patients in chronic Helicobacter pylori infection, concomitant changes in the gallbladder, pancreas, and liver were observed. Conclusions. The results of our own studies indicate a high frequency of pathological changes in the ultrasound picture of the liver parenchyma, the structure of the gallbladder and pancreas in patients with gastric and duodenal ulcer disease in chronic Helicobacter pylori infection. The results of clinical and laboratory studies showed that in the main group patients signs of cytolysis are determined in the form of a significant increase in transaminases, namely alanine transaminase and aspartate transaminase, indirect bilirubin, thymol test. The signs of cholestasis – an increase in gamma-glutamyltransferase and bilirubin, both direct and indirect, were present as well.
References
AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology. 2020;158(6):1822–1830. doi: https://doi.org/10.1053/j.gastro.2019.12.053
Arad D, Rosenfeld A, Magnezi R. Factors contributing to preventing operating room “never events”: a machine learning analysis. Patient Saf Surg. 2023 Mar 31;17(1):6. doi: 10.1186/s13037-023-00356-x
Alvarez CS, Florio AA, Butt J, et al. Associations between Helicobacter pylori with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala. Helicobacter. 2020;25(6):e12756. doi: https://doi.org/10.1111/hel.12756
Aron-Wisnewsky J, Vigliotti C, Witjes J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol. 2020;17:279–297. doi: https://doi.org/10.1038/s41575-020-0269-9
Cen C, Du Q, Luo B, Wang T, Su J, Qin X, Zhang W, Lu L, Liao Y, Huang Y, Liang Y. Helicobacter pylori causes gastric dysbacteriosis in chronic gastritis patients. Open Life Sci. 2024;19(1):20220839. doi: 10.1515/biol-2022-0839
Doulberis M, Srivastava S, Polyzos SA, et al. Active Helicobacter pylori infection is independently associated with nonalcoholic steatohepatitis in morbidly obese patients. J Clin Med. 2020;9(4):933. doi: https://doi.org/10.3390/jcm9040933
Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi: https://doi.org/10.1016/j.jhep.2020.03.039
Gubergrits NB, Belyaeva NV, Klochkov OE, Lukashevich GM, Fomenko PG. Drug-induced liver damage: from pathogenesis to treatment. Visnyk Klubu Pankreatolohiv. 2020;46(1):72–80. doi: https://doi.org/10.33149/vkp.2020.01.10
Hernández-Ceballos W, Cordova-Gallardo J, Mendez-Sanchez N. Gut microbiota in metabolic-associated fatty liver disease and in other chronic metabolic diseases. J Clin Transl Hepatol. 2021;9(2):227–238. doi: https://doi.org/10.14218/JCTH.2020.00131
Heydari K, Yousefi M, Alizadeh-Navaei R, et al. Helicobacter pylori infection and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Turk J Gastroenterol. 2022;33(3):171-181. doi: https://doi.org/10.5152/tjg.2022.21467
Ibrahim H, Afifi EBS, Galal AAA, Metwally MMM, Darwish WS. Ameliorative potential of quercetin on the possible adverse effects of ketoprofen. Open Vet J. 2025; 15(11):5594–5604. doi: 10.5455/OVJ.2025.v15.i11.16
Liu Y, Li D, Liu Y, Shuai P. Association between Helicobacter pylori infection and non-alcoholic fatty liver disease, hepatic adipose deposition and stiffness in Southwest China. Front Med (Lausanne). 2021;8:764472. doi: https://doi.org/10.3389/fmed.2021.764472
Mavilia-Scranton MG, Wu GY, Dharan M. Impact of Helicobacter pylori infection on the pathogenesis and management of nonalcoholic fatty liver disease. J Clin Transl Hepatol. 2023;11(3):670–674. doi: https://doi.org/10.14218/JCTH.2022.00362
Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71(9):1724–1762. doi: https://doi.org/10.1136/gutjnl-2022-327745
Meijuan Z, Yu P, Yuan J, Yu T, Sun D. Stomach ulcer caused by mistakenly oral medication of 14,400 mg ibuprofen: A case report. Medicine (Baltimore). 2023; 102(20): 33812. doi: 10.1097/MD.0000000000033812
Moroz VM, Shandra OA, Vastyanov RS, Yoltukhivsky MV, Omelchenko OD. Physiology. Vinnytsia : Nova Knyha, 2016: 722.
Tiron OI, Vastyanov RS, Horoshkov OV. Renal dysfunction pathogenetically based pharmacological correction using lipoprotein with sorbitol and HAES-LX-5 % hyperosmolar colloidal solutions in conditions of thyroid gland burning. World of Medicine and Biology. 2023;4(86):231-7. doi: 10.26724/2079-8334-2023-4-86-231-237
Shukhtina IN, Avramenko AA, Badiuk NS, Vasiuk VL. Credibility of application of various testing methods for chelicobacterial infection in patients with chronic non-atrophic gastritis, sufficient and not sufficient of chronic constipation. Aktual Probl Transp Med. 2021;2(64):45–55. doi: https://doi.org/10.5281/zenodo.5110583
